Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

BeOne Medicines (BEIGF) Long-Term Debt Issuances (2016 - 2025)

Historic Long-Term Debt Issuances for BeOne Medicines (BEIGF) over the last 9 years, with Q3 2025 value amounting to $885.0 million.

  • BeOne Medicines' Long-Term Debt Issuances changed N/A to $885.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $885.0 million, marking a year-over-year increase of 967576.49%. This contributed to the annual value of $9.1 million for FY2024, which is 5976.8% down from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Long-Term Debt Issuances is $885.0 million.
  • In the past 5 years, BeOne Medicines' Long-Term Debt Issuances ranged from a high of $885.0 million in Q3 2025 and a low of $155000.0 during Q2 2021
  • Moreover, its 5-year median value for Long-Term Debt Issuances was $9.9 million (2021), whereas its average is $121.3 million.
  • As far as peak fluctuations go, BeOne Medicines' Long-Term Debt Issuances plummeted by 9968.7% in 2021, and later soared by 52090.05% in 2022.
  • Over the past 5 years, BeOne Medicines' Long-Term Debt Issuances (Quarter) stood at $6.0 million in 2021, then skyrocketed by 520.9% to $37.4 million in 2022, then crashed by 81.99% to $6.7 million in 2023, then skyrocketed by 34.5% to $9.1 million in 2024, then surged by 9675.76% to $885.0 million in 2025.
  • Its Long-Term Debt Issuances was $885.0 million in Q3 2025, compared to $9.1 million in Q1 2024 and $6.7 million in Q3 2023.